Educational information only. Not medical advice. Talk to a qualified healthcare professional before using any compound. Disclaimer

LimitlessLab
Search the library Wishlist Cart, items: 0
Tesamorelin

Growth Hormone & Muscle

Tesamorelin

Also known as Egrifta, Egrifta SV, Egrifta WR, TH9507

Strong human evidenceApproved medicineWADA prohibited

Price range: €54 through €88

Discussed for: Reduce belly (visceral) fat.

Sequence: not listed. Modified or non-standard residues are left out on purpose.

Effect strengthHow hard it acts on the body6/10
Proof levelHow well that is shown in humans9/10
Risk levelHow much can go wrong4/10

Editorial 1 to 10 estimates from published research, not measured values. How to read these

Save to wishlist
Save to wishlist

01 / Identity

What it is

Tesamorelin is a synthetic GHRH analog (44 aa). Main reported uses: reduce belly (visceral) fat. Current status: FDA-approved (HIV lipodystrophy); other uses off-label.

Molecule type
Synthetic GHRH analog (44 aa)
How it is taken
Injection (SC)
Other names
Egrifta, Egrifta SV, Egrifta WR, TH9507

Route only. This library does not publish doses or protocols.

02 / Mechanism

How it is thought to work

Stabilized GHRH analog that raises GH and IGF-1 and reduces visceral fat

03 / Potential benefits

What people use it for

Reduce belly (visceral) fat

Strong human evidence

Large human trials exist. Effects are well described, at least for the approved use.

Listed uses are what people use it for, not proven outcomes.

04 / Known risks

Side effects and risks

Joint pain, swelling, raised blood sugar, injection-site reactions

Risk level 4 of 10

Moderate risk score: real side effects are known, and long-term safety is not settled.

Unknown long-term effects count as a risk, not as a clean record.

05 / Regulatory

Regulatory status

Status
Approved medicine
Details
FDA-approved (HIV lipodystrophy); other uses off-label
Sport (WADA)
Yes: S2 (peptide hormones / GH factors)

Status reflects information up to mid-2026 and changes over time. Check current sources.

06 / Evidence quality

How good is the evidence?

Strong: large human trials

How we grade evidence

07 / Notes and sources

Notes and sources

  • Growth-factor peptides carry a theoretical risk of feeding existing cancers.
  • Anyone using compounds like this regularly should have medical supervision and bloodwork (for example IGF-1, glucose and HbA1c, hormones, lipids).
  • Source: Peptide Reference Table, an editorial review of published research up to mid-2026. Scores are 1 to 10 editorial estimates, not measured values. Regulatory and WADA status change over time.

Educational information only. Not medical advice. Talk to a qualified healthcare professional before using any compound.

Related compounds